all you current CV people

Ex BMS here...as in diabetes...do all you know how to spell Pfizer....better get used to it!! Read the writing on the wall. All the changes you are seeing are way to familiar to what happened in Diabetes!!!

 

I heard that also. 2015?

 

By year end 2015 CV will be sold. I won't post again, it's a done deal.

 

And who are you? How do you know this to be a fact?

 

I'm the same person who told you NSS was going away, which no one believed at the time. I also told you what a shit investment the diabetes franchise was, and presto, Lamberto sold it. Nuff said.

 

This dude is spot on!!!!! Leave now.

 

Not saying it can't happen but why would any big pharma company sell a drug that has life until 2023? It's growing and is getting new indications. Would make no sense to sell it now..

 

Take another look at the diabetes portfolio & you may want to reconsider your point of view. CV is done.

 

simply put--- CV has no pipeline for the future. You're toast!

 

you are a moron.
Eliquis has 12 + years, most likely more with new indications. What do you know what the pipeline will be like for cardiovascular over the next decade? Do you think the current healthcare market has cured and solved all of world's cardio needs?
you are the reason why pharma reps get a bad rep. please go back to enterpise.

 

Since you seem to have all the answers why don't you tell us what the bms cv pipeline looks like & how that fits the biopharma model.

 

I am not the poster whom you refer to as the know it all, however I feel compelled to respond.

You have valid points that Pfizer is well know to either out right buy a company whom it believes can give it a strategic advantage, or make it/ keep it the largest pharma company in the world. You are also correct that BMS by selling off the diabetes division/products will not hesitate to give the boot to areas that it feels will give it a strategic advantage or are more in line with it's therapeutic areas of focus.

However, the Cardiovascular line with Eliquis as stated above, does have a long product life cycle, does appear have new indications coming, sales are trending upward, the DTC campaign is proving effective, and recent press has been positive.

With respect to the pipeline, we all know in this industry that most of these molecules never make it to market, but BMS DOES have a few cardiovascular products in different phases of development. See below

LXR Modulators (cardiovascular)
PCSK9 Adnectin (cardiovascular)
CCR2 / 5 Antagonists (cardiovascular)
IKur Antagonists (cardiovascular)
Factor XIa Inhibitor (Parenteral) (cardiovascular)
Factor XIa Inhibitor (Oral) (cardiovascular)

They are for Heart Failure, a New type of Anticoagulant ( next Generation), a product for AFIB, an atherosclerosis drug that may raise HDL without hepatic stenosis and hypertriglyceridemia, and other potential products for Atherosclerosis.

We may be "toast" as you seem to think but just maybe the other poster who seems to be a bit more positive on the future outlook is correct.

We reps in the BMS Cardiovascular division appreciate your insight and your opinion. Perhaps you can try to do the same.

 

160 jobs gone in Ireland. Just announced - 130 From the Cruiserath Facility which will be closing end of 2015 and 30 from the Swords site

 

Spot On. Each situation is different. Abilify was going out and we got an offer we couldn't refuse. Diabetes was sold due to the low profit and high liability. BMS has already said they are keeping and developing Eliquis.

 

The issue is; can Lamberto hit EPS goals to maximize/ obtain his total compensation package potential? If he needs to sell Eliquis to Pfizer to meet those goals, he will. Like any good CEO, he doesn't know how long he will have the job, family to set up for life, etc - his primary objective is to make as much money as he can, as quickly as he can. To think otherwise is naive. Let history be your guide - Heimbold, Dolan, Cornelius - EVERYONE ON THEM PUT THEMSELVES FIRST, over shareholders & employees. It's a great gig if you can get it.

 

Douchebag,

Who cares if Eliquis has many new indications, it will be Pfizer's ownership this year. Grow up and stop drinking the kool-aid. By the way, I work for your company.

 

Eliquis has performed terribly overall considering what the drug offered. Salesforce has not done what they could to sell drug

 

leave now losers we will stuff your heads with moss

 

Don't worry Xarelto rep we are going to crush you

 

Ditto, Our market share is climbing daily and the momentum is growing as physicians are becoming aware of Eliquis's unique superiority in both efficacy and safety. Journal articles are consistently favoring it and the data speaks.